DE69927249D1 - Induzierendes alphavirengen- expressionssystem - Google Patents

Induzierendes alphavirengen- expressionssystem

Info

Publication number
DE69927249D1
DE69927249D1 DE69927249T DE69927249T DE69927249D1 DE 69927249 D1 DE69927249 D1 DE 69927249D1 DE 69927249 T DE69927249 T DE 69927249T DE 69927249 T DE69927249 T DE 69927249T DE 69927249 D1 DE69927249 D1 DE 69927249D1
Authority
DE
Germany
Prior art keywords
rna molecules
untranslated
methods
heterologous proteins
alphavirengen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69927249T
Other languages
English (en)
Other versions
DE69927249T2 (de
Inventor
A Renner
Lars Nieba
Marco Boorsma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytos Biotechnology AG
Original Assignee
Cytos Biotechnology AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytos Biotechnology AG filed Critical Cytos Biotechnology AG
Application granted granted Critical
Publication of DE69927249D1 publication Critical patent/DE69927249D1/de
Publication of DE69927249T2 publication Critical patent/DE69927249T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/10—Vectors comprising a special translation-regulating system regulates levels of translation
    • C12N2840/105—Vectors comprising a special translation-regulating system regulates levels of translation enhancing translation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69927249T 1998-03-27 1999-03-25 Induzierendes alphavirengen- expressionssystem Expired - Lifetime DE69927249T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7956298P 1998-03-27 1998-03-27
US79562P 1998-03-27
PCT/IB1999/000523 WO1999050432A1 (en) 1998-03-27 1999-03-25 Inducible alphaviral gene expression system

Publications (2)

Publication Number Publication Date
DE69927249D1 true DE69927249D1 (de) 2005-10-20
DE69927249T2 DE69927249T2 (de) 2006-06-29

Family

ID=22151327

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69927249T Expired - Lifetime DE69927249T2 (de) 1998-03-27 1999-03-25 Induzierendes alphavirengen- expressionssystem
DE1066395T Pending DE1066395T1 (de) 1998-03-27 1999-03-25 Induzierendes alphavirengen- expressionssystem

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE1066395T Pending DE1066395T1 (de) 1998-03-27 1999-03-25 Induzierendes alphavirengen- expressionssystem

Country Status (10)

Country Link
US (2) US7005275B2 (de)
EP (1) EP1066395B1 (de)
JP (2) JP2002509729A (de)
AT (1) ATE304603T1 (de)
AU (1) AU757549B2 (de)
CA (1) CA2325564A1 (de)
DE (2) DE69927249T2 (de)
IL (1) IL138615A0 (de)
NZ (1) NZ507195A (de)
WO (1) WO1999050432A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69927249T2 (de) * 1998-03-27 2006-06-29 Cytos Biotechnology Ag Induzierendes alphavirengen- expressionssystem
US7241617B2 (en) * 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
AU4395599A (en) * 1998-07-03 2000-01-24 Dnavec Research Inc. (-)-strand rna virus vector for nerve cell
JP2002521461A (ja) 1998-07-29 2002-07-16 インビトロゲン・コーポレーション Ｒｎａウイルスを用いる組換えタンパク質の調節発現
EP1226238A2 (de) * 1999-10-27 2002-07-31 Cytos Biotechnology AG Methoden zur produktion von divergierenden populationen von nukleinsäuren und proteinen
AU1647501A (en) 1999-12-10 2001-06-18 Cytos Biotechnology Ag Replicon based activation of endogenous genes
WO2001085208A2 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
US7320793B2 (en) 2001-01-19 2008-01-22 Cytos Biotechnology Ag Molecular antigen array
JP4790984B2 (ja) * 2001-09-06 2011-10-12 アルファヴァックス，インコーポレイテッド アルファウイルスレプリコンベクター系
EP1530585A2 (de) * 2002-08-22 2005-05-18 Cytos Biotechnology AG Induzierbares alphaviral/orip basiertes gen expressionssystem
WO2005005644A1 (en) 2003-07-11 2005-01-20 Cytos Biotechnology Ag Gene expression system
US20080096274A1 (en) * 2006-10-24 2008-04-24 Guangpu Li Recombinant alphavirus vectors and methods of using same
WO2016209989A1 (en) * 2015-06-26 2016-12-29 The Regents Of The University Of California Methods for rna promoter identification
US9859156B2 (en) * 2015-12-30 2018-01-02 Taiwan Semiconductor Manufacturing Co., Ltd. Interconnection structure with sidewall dielectric protection layer
GB201603374D0 (en) 2016-02-26 2016-04-13 Ucl Business Plc Packaging cell
CN116134131A (zh) 2019-12-31 2023-05-16 伊利克斯根治疗公司 核酸和蛋白质向细胞和组织的基于温度的瞬时递送
WO2023034881A1 (en) * 2021-09-02 2023-03-09 Elixirgen Therapeutics, Inc. Temperature-controllable, rna immunotherapeutic for cancer
CN113846113B (zh) * 2021-09-09 2022-09-13 臻赫医药(杭州)有限公司 一种有限自我复制mRNA分子系统、制备方法及应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ210501A (en) 1983-12-13 1991-08-27 Kirin Amgen Inc Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence
US5091309A (en) * 1986-01-16 1992-02-25 Washington University Sindbis virus vectors
US5217879A (en) * 1989-01-12 1993-06-08 Washington University Infectious Sindbis virus vectors
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5458878A (en) 1990-01-02 1995-10-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services P. exotoxin fusio proteins have COOHG220101al alterations which increase cytotoxicity
WO1994017813A1 (en) 1993-02-08 1994-08-18 Paravax, Inc. Defective sindbis virus vectors that express toxoplasma gondii p30 antigens
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
ATE437942T1 (de) 1993-09-15 2009-08-15 Novartis Vaccines & Diagnostic Rekombinante alphavirus-vektoren
US5532154A (en) 1994-03-21 1996-07-02 Research Development Foundation Mutated alpha virus
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5792462A (en) 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
US6451592B1 (en) 1996-04-05 2002-09-17 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP1997900A3 (de) 1996-04-05 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Rekombinante Vektoren auf Alphavirus-Basis mit reduzierter Hemmung der zellulären Makromolekularsynthese
US5811407A (en) * 1997-02-19 1998-09-22 The University Of North Carolina At Chapel Hill System for the in vivo delivery and expression of heterologous genes in the bone marrow
DE69927249T2 (de) * 1998-03-27 2006-06-29 Cytos Biotechnology Ag Induzierendes alphavirengen- expressionssystem

Also Published As

Publication number Publication date
AU2848199A (en) 1999-10-18
IL138615A0 (en) 2001-10-31
AU757549B2 (en) 2003-02-27
DE69927249T2 (de) 2006-06-29
EP1066395A1 (de) 2001-01-10
DE1066395T1 (de) 2002-04-04
US20030053988A1 (en) 2003-03-20
US20060024788A1 (en) 2006-02-02
WO1999050432A1 (en) 1999-10-07
NZ507195A (en) 2003-07-25
CA2325564A1 (en) 1999-10-07
JP2005323620A (ja) 2005-11-24
JP2002509729A (ja) 2002-04-02
ATE304603T1 (de) 2005-09-15
US7005275B2 (en) 2006-02-28
EP1066395B1 (de) 2005-09-14

Similar Documents

Publication Publication Date Title
DE69927249D1 (de) Induzierendes alphavirengen- expressionssystem
Spirin et al. A continuous cell-free translation system capable of producing polypeptides in high yield
Kerekatte et al. Cleavage of Poly (A)-binding protein by coxsackievirus 2A protease in vitro and in vivo: another mechanism for host protein synthesis shutoff?
JP6284181B2 (ja) 環状ｒｎａ及びタンパク質の製造方法
Paterson et al. Efficient translation of prokaryotic mRNAs in a eukaryotic cell-free system requires addition of a cap structure
BR0007414A (pt) Expressão e exportação de proteìnas antiobesidade como proteìnas de fusão fc
BRPI0511118A (pt) polipeptìdeos de haemophilus influenzae não transcritos
BR0010725A (pt) Expressão e exportação de proteìnas de interferon-alfa como proteìnas de fusão de fc
BR9914374A (pt) Sequências genÈmicas de neisseria e métodos para seu uso
NO20064059L (no) Albumin fusjonsproteiner
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
BRPI0411475A (pt) adições de código genético de aminoácido reativo não natural
DK1005540T3 (da) IKK-beta-proteiner, nukleinsyrer og fremgangsmåder
Nass Modified nucleosides and cancer
WO1994007917A1 (en) A NOVEL β1->6 N-ACETYLGLUCOSAMINYLTRANSFERASE, ITS ACCEPTOR MOLECULE, LEUKOSIALIN, AND A METHOD FOR CLONING PROTEINS HAVING ENZYMATIC ACTIVITY
HUP9800329A2 (hu) Nukleinsavkonstrukciók strukturális gének sejtciklus-függő módon szabályozott expresszálására
EP0232523A3 (en) Dna sequences which encode for proteins with the biological activity of husi-type i inhibitors, their production by gene technology and drugs containing these proteins
DE60127561D1 (de) Phagen-abhängige superproduktion biologisch aktiver proteine und peptide
DE69928395D1 (de) Cyclin-e2 proteine und dafür kodierende gene
HUP0302481A2 (hu) Virulencia gének, fehérjék és alkalmazásuk
Carlson et al. 1-Methylguanosine in place of Y base at position 37 in phenylalanine tRNA is responsible for its shiftiness in retroviral ribosomal frameshifting
CO5650177A2 (es) Constructos geneticos y composiciones que comprenden rre y cte y usos de estos
HUP0304053A2 (hu) Új expressziós vektorok és azok alkalmazása
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
Bargahi et al. Effect of shark cartilage derived protein on the NK cells activity

Legal Events

Date Code Title Description
8364 No opposition during term of opposition